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ABSTRACT OF THESIS

ACUTE KIDNEY INJURY IN PATIENTS TREATED WITH VANCOMYCIN AND
PIPERACILLIN-TAZOBACTAM: A RETROSPECTIVE COHORT ANALYSIS

Empiric antimicrobial therapy often consists of the combination of Gram-positive
coverage with vancomycin (VAN) and Gram-negative coverage, specifically an antipseudomonal beta-lactam, such as piperacillin-tazobactam (PTZ). Nephrotoxicity is
commonly associated with VAN therapy; however, recent reports demonstrate increasing
nephrotoxicity rates among patients treated with the combination of VAN and PTZ. This
study evaluated the effect of the VAN/PTZ combination on acute kidney injury (AKI), as
defined by the RIFLE criteria, compared to VAN and PTZ monotherapies.
Overall, 11,650 patients were analyzed, with 1,647 (14.1%) AKI cases occurring.
AKI was significantly more frequent in the VAN/PTZ group (21%) compared to either
monotherapy group (VAN 8.3%, PTZ 7.8%, p<0.001 for both). Combination therapy was
independently associated with higher AKI odds compared to monotherapy with either
agent (aOR=2.03; 95% CI 1.74-2.39; aOR=2.31; 95% CI 1.97-2.71, for VAN and PTZ,
respectively). Receipt of concomitant nephrotoxic drugs were independently associated
with increased AKI rates, as were increased duration of therapy, length of hospital stay,
increasing severity of illness, and increasing baseline renal function.
VAN combined with PTZ was associated with twice the odds of AKI
development compared to either agent as monotherapy. This demonstrates the need for
judicious use of combination empiric therapy.
KEYWORDS: Antimicrobial stewardship, Vancomycin, Piperacillin-tazobactam,
Acute Kidney Injury, Electronic health record
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Chapter One: Introduction
The glycopeptide antibiotic vancomycin is commonly utilized in empiric coverage
for methicillin-resistant Staphylococcus aureus (MRSA) in many types of infections.
Literature from a variety of patient populations reports nephrotoxicity associated with
vancomycin, targeting troughs greater than 15 µg/mL, to occur in 5 to 43% of patients.[1]
In a study of critically ill patients, acute kidney injury (AKI) was found in 21% of patients
receiving vancomycin, with increasing duration of vancomycin treatment, greater
vancomycin levels, concomitant vasoactive medication administration, and intermittent
infusion methods being associated with higher odds of AKI.[2] A recent report from adult
internal

medicine

patients

estimated

the

incidence

of

vancomycin-associated

nephrotoxicity at 13.6% and implicated concomitant piperacillin-tazobactam therapy as a
key factor in these patients.[3]
Further studies have explored the interaction between empiric beta-lactam and
vancomycin therapy, showing mixed results. Reports of AKI associated with the
combination of vancomycin and piperacillin-tazobactam range from 16.3 to 34.8% [4-8],
while the cefepime-vancomycin combination is reported to range from 12.5 to 13.3%. [5,6]
While vancomycin monotherapy groups were well represented, only one of these studies
compared the piperacillin-tazobactam-vancomycin combination to a control group of
piperacillin-tazobactam monotherapy.[7]
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Chapter Two: Methods
This is a retrospective cohort study of adult patients conducted at the University of
Kentucky Chandler Medical Center (UKMC) from September 1, 2010 through August 31,
2014. Patients were included if they: were at least 18 years of age on admission; remained
hospitalized for at least 48 hours; received vancomycin combined with piperacillintazobactam (VAN/PTZ), vancomycin alone (VAN), or piperacillin-tazobactam alone
(PTZ); and had at least 48 hours of therapy (and 48 hours of overlapping therapy in the
VAN/PTZ group). Patients were excluded if they had underlying chronic kidney disease,
were receiving renal replacement therapy prior to admission, had a diagnosis of cystic
fibrosis, or were pregnant. Additionally, patients were excluded if: they presented with
AKI, defined as baseline creatinine clearance less than 30 mL/min, or if baseline creatinine
clearance was greater than four times the standard deviation from the mean; serum
creatinine values were not obtained during admission; and if AKI occurred prior to therapy
initiation, within 48 hours of initiation, or greater than 7 days after treatment was
discontinued. Patients were followed throughout their stay until time of discharge.

Data Source
Patient data were collected from the University of Kentucky Center for Clinical and
Translational Science Enterprise Data Trust (EDT). The EDT contains clinical data from
the inpatient population of UKMC from 2006 to present. Data stored and updated nightly
by the EDT includes: demographics, financial classification (Medicare, Medicaid, private
insurance), provider-level detail (service line), medical diagnosis (International
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Classification of Diseases 9 [ICD-9] codes), medical procedures (Current Procedural
Terminology [CPT] codes), lab tests and results, medication administration details, visit
details (age, length of stay, etc.), and vital signs. This study was approved by the UKMC
Institutional Review Board.
Data collected for each patient included: demographic data, visit details (length of
stay, admitting and primary diagnosis codes, etc.), severity of underlying illness as defined
by the Charlson Comorbidity Index (CCI), all serum creatinine levels drawn per visit,
medication administration information (dose, date, and time administered), all vancomycin
trough levels, receipt of other nephrotoxic agents, blood pressures, and receipt of
vasopressors.

Outcome Ascertainment
AKI was defined based on the RIFLE criteria (Risk, Injury, Failure, Loss, Endstage)[9] with risk defined as a 25 to 50% decrease in estimated glomerular filtration rate
(GFR), injury as a 50 to 75% decrease in estimated GFR, and failure defined as a greater
than 75% decrease in estimated GFR. Loss and end-stage classifications were not assessed
due to the follow-up period of this study. The adjusted Cockcroft and Gault equation [10]
was used to estimate GFR due to the inconsistency of weight availability in the dataset.
Baseline creatinine clearance was calculated with the first serum creatinine obtained, and
the minimum creatinine clearance was calculated using the maximum serum creatinine
during each patient’s visit; the percent decrease in creatinine clearance was calculated from
these two values. AKI status was defined as meeting any of the RIFLE criteria. Mortality
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was assessed for all patients and defined as the composite of in-hospital mortality and
discharge or transfer to hospice care.

Exposure Ascertainment
Hypotension exposure was defined as experiencing one of the following: mean
arterial blood pressure less than 60 mmHg, a diagnosis of hypotension by a physician, or
receipt of vasopressors or inotropic agents. Days of therapy for each drug was obtained,
and combination days of therapy was calculated by including only those days in which the
patient received both medications. Total days of therapy was calculated by the sum of all
days receiving at least one of the study agents. The average daily vancomycin dose was
calculated for each patient by taking the sum of all vancomycin doses received and dividing
by the days of vancomycin therapy. Exposure to other nephrotoxic agents (acyclovir,
angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists,
aminoglycosides, amphotericin B, cyclosporine, foscarnet, loop diuretics, nonsteroidal
anti-inflammatory drugs [NSAIDs], sulfonamides, tacrolimus, and tenofovir) was defined
as receipt of at least one dose of the agent during hospitalization.

Statistical Analysis
Characteristics between groups were described with basic descriptive statistics.
Continuous variables were compared with one-way ANOVA or the Kruskal-Wallis test.
Categorical variables were compared with χ2 or Fisher’s exact test. Yearly AKI trends were
assessed with Pearson’s correlation coefficient. Univariate models for all covariates were
4

created with probability of AKI as the outcome. Covariates significant after univariate were
then incorporated into the multivariate model, which was subsequently adjusted to achieve
the highest predictive accuracy by minimizing the Akaike information criterion (AIC).
Model fit was assessed with a standardized Hosmer-Lemeshow goodness of fit test.[11]
All statistical analyses were completed with RStudio v0.98 running R v3.1.2 (R Foundation
for Statistical Computing, Vienna, Austria)[12]. All tests were two-tailed and significance
was defined at an alpha of 0.05.

Role of Funding Source
The project described was supported by the National Center for Advancing
Translational Sciences, National Institutes of Health, through grant number
UL1TR000117. The content is solely the responsibility of the authors and does not
necessarily represent the official views of the NIH.

5

Chapter Three: Results
Baseline Patient Characteristics
Of 17,879 patients initially screened, 11,650 patients were evaluated, of which
5,497 received VAN and PTZ (VAN/PTZ), 3,055 received VAN alone, and 3,098 received
PTZ alone (Figure 2). Table 1 contains basic demographic information. The average age
of patients was 52.5 ± 16.8 years with 6,242 (53.6%) males. Patients receiving VAN/PTZ
had higher CCIs than either monotherapy group and had significantly increased length of
hospitalization. While patients in the combination therapy group were more likely to
experience some level of hypotension, concomitant nephrotoxic agent exposure was more
common in the VAN monotherapy group.
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FIGURE 1: Patient exclusion flowchart
Patients receiving VAN,
PTZ, or VAN/PTZ
N = 17,874
-

Adults ≥ 18

-

No pregnancy

-

No CF

-

No diagnosed CKD or

Patients excluded
N = 6,224

dialysis

-

Less than 48 hours of treatment = 1,685

-

Combination therapy < 48 hours = 1,508

-

Length of stay < 48 hours = 1,398

-

Baseline CrCl < 30 mL/min = 449

-

AKI within 48 hours of treatment = 446

-

No serum creatinine values = 290

-

AKI occurred prior to treatment = 219

-

AKI occurred > 7 days after treatment

Final population
N=11,650
-

VAN = 3,055

-

PTZ =3,098

-

VAN/PTZ = 5,497

discontinued = 199
-

Outlier baseline CrCl = 30
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TABLE 1: Baseline patient characteristics
Outcome

VAN

PTZ

VAN/PTZ

(N=3,055)

(N=3,098)

(N=5,497)

Age (years) [Mean
52.5 (16.9)

53.3 (17.5)

52.0 (16.3)

18-29

333 (10.9%)

379 (12.2%)

594 (10.8%)

30-49

940 (30.8%)

837 (27.0%)

1736 (31.6%)

50-64

984 (32.2%)

1034 (33.4%)

1904 (34.6%)

65-79

630 (20.6%)

632 (20.4%)

1019 (18.5%)

≥80

168 (5.5%)

216 (7.0%)

244 (4.4%)

1462 (47.9%)

1523 (49.2%)

3257 (59.3%)

2 (0-4)

2 (0-5)

3 (1-5)

100.9 (40.4)

100.1 (42.7)

101.9 (43.6)

(± SD)]
Age group (years)

Male gender
Charlson
Comorbidity Index
[Median (IQR)]
Baseline creatinine
clearance (mL/min)
[Mean (±SD)]*
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Outcome

VAN

PTZ

VAN/PTZ

(N=3,055)

(N=3,098)

(N=5,497)

CrCl group (mL/min)
30-59

394 (12.9%)

528 (17.0%)

855 (15.6%)

60-89

984 (32.2%)

888 (28.7%)

1539 (28.0%)

≥90

1677 (54.9%)

1682 (54.3%)

3103 (56.4%)

646 (21.1%)

867 (28.0%)

1487 (27.1%)

Elective

904 (29.6%)

398 (12.8%)

644 (11.7%)

Emergency

1329 (43.5%)

1692 (54.6%)

2956 (53.8%)

Trauma

102 (3.3%)

137 (4.4%)

524 (9.5%)

Urgent

720 (23.6%)

871 (28.1%)

1373 (25.0%)

447 (14.6%)

442 (14.3%)

1560 (28.4%)

98 (3.2%)

225 (7.3%)

312 (5.7%)

5 (3-9)

5 (3-9)

7 (4-14)

3 (2-5)

4 (3-6)

5 (4-8)

Transfer from
outside facility
Admission type

Hypotension
exposure
Dehydration
diagnosis
Length of Stay
(days) [Median
(IQR)]
Total Days of
Therapy (days)
[Median (IQR)]
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Outcome

VAN

PTZ

VAN/PTZ

(N=3,055)

(N=3,098)

(N=5,497)

Length of Stay (days)
≤7

2084 (68.2%)

2144 (69.2%)

2760 (50.2%)

8-14

596 (19.5%)

641 (20.7%)

1438 (26.2%)

15-21

182 (6.0%)

179 (5.8%)

637 (11.6%)

>21

193 (6.3%)

134 (4.3%)

662 (12.0%)

1970 (64.5%)

1434 (46.3%)

3343 (60.8%)

Acyclovir

202 (6.6%)

19 (0.6%)

109 (2.0%)

ACE-inhibitor

595 (19.5%)

545 (17.6%)

1142 (20.8%)

ARB

159 (5.2%)

133 (4.3%)

167 (3.0%)

Aminoglycoside 336 (11.0%)

126 (4.1%)

630 (11.5%)

Amphotericin B

30 (1.0%)

11 (0.4%)

78 (1.4%)

Cyclosporine*

8 (0.3%)

12 (0.4%)

13 (0.2%)

Foscarnet*

4 (0.1%)

1 (0.03%)

5 (0.1%)

Loop diuretic

594 (19.4%)

607 (19.6%)

1828 (33.3%)

NSAID

874 (28.6%)

309 (10.0%)

752 (13.7%)

Sulfonamide

19 (0.6%)

18 (0.6%)

95 (1.7%)

Tacrolimus

34 (1.1%)

75 (2.4%)

108 (2.0%)

Tenofovir*

27 (0.9%)

18 (0.6%)

29 (0.5%)

Nephrotoxic agent
exposure
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Footnote for Table 1:
Reported values are N (%) unless otherwise specified; All values are significantly different
by standard tests unless denoted by * where p>0.05; SD: standard deviation; IQR:
interquartile range; CrCl: creatinine clearance; ACE: angiotensin converting enzyme;
ARB: angiotensin receptor blocker; NSAID: non-steroidal anti-inflammatory drug

Unadjusted Acute Kidney Injury Incidence
RIFLE-defined AKI occurred in 1,647 (14.1%) across the entire cohort. AKI
occurred in 21% of VAN/PTZ patients, 8.3% of VAN patients, and 7.8% of PTZ patients
(p<0.0001). RIFLE-defined Risk, Injury, and Failure occurred more frequently in the
VAN/PTZ cohort compared to the VAN and PTZ monotherapy groups (Figure 2). There
were no differences in AKI rates between years studied (r2=0.4732, p=0.2). Patients in the
VAN/PTZ group experienced AKI on average of 8.0 days after treatment initiation,
compared to 8.7 and 5.2 days for VAN and PTZ monotherapy groups, respectively. The
composite of in-hospital mortality and transfer to hospice care was more common in
VAN/PTZ patients (9.6%) compared to monotherapy groups (VAN 3.9%, PTZ 3.4%),
most likely due to the increased severity of illness.
Factors associated with AKI in univariate analyses included treatment with
VAN/PTZ, days of therapy, baseline creatinine clearance, transfer from outside hospitals,
CCI, admission type, length of hospitalization, dehydration exposure, and hypotension
exposure. Exposure to aminoglycosides, amphotericin B, ACE inhibitors, NSAIDs,
tacrolimus, foscarnet, loop diuretics, sulfonamides, and tenofovir were all associated with
increased odds of AKI in simple univariate logistic regression. Gender, age, year of
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treatment, angiotensin II receptor antagonist exposure, and cyclosporine exposure were not
significantly associated with AKI incidence.
FIGURE 2: Unadjusted incidence of AKI
25%

Percent of Patients

p<0.001
20%
p<0.001

15%

p<0.001

10%

p<0.001
5%
0%
Overall

Risk
Injury
Acute Kidney Injury Classification

Failure

Vancomycin monotherapy
Piperacillin/tazobactam monotherapy
Vancomycin plus Piperacillin/Tazobactam combination therapy

Adjusted Acute Kidney Injury Incidence
After multivariate logistic regression, VAN/PTZ therapy was associated with
increased odds of AKI compared to VAN and PTZ monotherapies (aORVAN=2.03; 95%
CIVAN 1.74-2.39; aORPTZ=2.31; 95% CIPTZ 1.97-2.71). No difference in AKI incidence was
observed between VAN and PTZ groups (aORPTZ compared to VAN=0.88; 95% CI 0.72-1.07).
Table 2 describes the relationship between AKI and other covariates included in the model.
Increased odds of AKI were seen with concomitant administration of amphotericin B,
tacrolimus, loop diuretics, and tenofovir. Patients admitted urgently and emergently were
at higher risk of AKI, while those admitted via the trauma center were less likely to
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experience AKI compared to patients who were electively admitted. Increased length of
stay and duration of therapy were both associated with increased likelihood of AKI,
independent of treatment group; however, durations of therapy beyond 12 days was not
associated with increased AKI. Hypotension, as previously defined, and diagnosed
dehydration both independently increased AKI odds. Aside from those greater than 80
years old, increasing age was not associated with increased AKI risk. No evidence of
overfitting was observed with the standardized Hosmer-Lemeshow p-value of 0.33, and
the model provides good predictive accuracy with a c-statistic of 0.787.
TABLE 2: Univariate and multivariate association between combination VAN/PTZ
therapy and AKI odds independent of other baseline covariates
Covariate

Unadjusted
OR

95% CI

Adjusted
p

OR

95% CI

p

Treatment group
VAN/PTZ

(ref)

(ref)

PTZ

0.34

0.29 - 0.39

<0.001 0.49

0.42 - 0.58 <0.001

VAN

0.32

0.27 - 0.37

<0.001 0.43

0.37 - 0.51 <0.001

Gender
Female
Male

(ref)
0.99

0.89 - 1.10

0.896

Age (years)
18-29

(ref)

(ref)

30-49

1.09

0.91 - 1.32

0.361

0.98

0.80 - 1.21 0.862

50-64

1.23

1.02 - 1.48

0.031

1.04

0.84 - 1.30 0.697
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Covariate

Unadjusted

Adjusted

OR

95% CI

p

OR

95% CI

p

65-79

1.11

0.91 - 1.36

0.316

1.17

0.92 - 1.50 0.201

≥ 80

1.12

0.84 - 1.47

0.427

1.8

1.28 - 2.52 0.001

1.07

1.06 - 1.09

<0.001 1.05

Age (years)

CCI (per point)

1.03 - 1.07 <0.001

Baseline CrCl
(mL/min)
30-59

(ref)

(ref)

60-89

1.02

0.85 - 1.23

0.816

1.4

≥ 90

1.7

1.45 - 2.01

<0.001 3.36

1.14 - 1.72 0.002
2.75 - 4.14 <0.001

Admission type
Elective

(ref)

(ref)

Emergency

1.19

1.02 - 1.39

0.033

1.21

1.01 - 1.45 0.038

Trauma

1.03

0.79 - 1.33

0.82

0.49

0.37 - 0.65 <0.001

Urgent

1.63

1.38 - 1.94

<0.001 1.39

1.14 - 1.71 0.001

1.56

1.39 - 1.74

<0.001 1.14

0.99 - 1.32 0.06

2.81

2.52 - 3.15

<0.001 1.59

1.39 - 1.82 <0.001

1.29

1.04 - 1.59

0.018

Transfer from
outside facility
Hypotension
exposure
Dehydration
exposure

14

1.33

1.05 - 1.68 0.017

Covariate

Unadjusted

Adjusted

OR

95% CI

p

OR

95% CI

p

Acyclovir

1.22

0.90 - 1.63

0.182

1.05

0.75 - 1.44 0.791

Aminoglycoside

1.89

1.62 - 2.20

<0.001 1.15

0.96 - 1.38 0.119

Amphotericin B

4.35

2.99 - 6.27

<0.001 2.22

1.45 - 3.37 <0.001

ACE inhibitor

1.34

1.18 - 1.51

<0.001 1.15

1.00 - 1.32 0.052

ARB

0.87

0.65 - 1.15

0.347

1.18

0.86 - 1.60 0.301

Cyclosporine

1.35

0.50 - 3.06

0.506

0.78

0.24 - 2.10 0.642

Foscarnet

6.09

1.69 - 21.92

0.004

1.98

0.41 - 9.46 0.387

Loop diuretic

3.51

3.15 - 3.91

<0.001 2.04

NSAID

0.82

0.71 - 0.95

0.009

0.98

0.83 - 1.16 0.848

Sulfonamide

1.8

1.18 - 2.68

0.005

1.38

0.86 - 2.15 0.163

Tacrolimus

2.66

1.97 - 3.56

<0.001 2.08

Tenofovir

1.96

1.12 - 3.28

0.013

Nephrotoxic drug
exposures

Year of admission
2010

(ref)

2011

0.85

0.69 - 1.05

0.127

2012

0.95

0.78 - 1.18

0.657

2013

0.87

0.70 - 1.07

0.176

2014

0.84

0.67 - 1.05

0.121

15

1.85

1.79 - 2.33 <0.001

1.45 - 2.96 <0.001
1.00 - 3.29 0.043

Covariate

Unadjusted
OR

95% CI

Adjusted
p

OR

95% CI

p

Duration of therapy
(days)
2-3

(ref)

(ref)

4-5

1.81

1.55 - 2.13

<0.001 1.32

1.12 - 1.56 0.001

6-7

3.23

2.74 - 3.81

<0.001 1.79

1.49 - 2.15 <0.001

8-9

5.09

4.22 - 6.13

<0.001 2

1.61 - 2.48 <0.001

10-11

5.94

4.71 - 7.46

<0.001 1.95

1.50 - 2.54 <0.001

12-13

5.25

3.84 - 7.12

<0.001 1.41

0.99 - 1.98 0.054

≥ 14

5.31

4.19 - 6.72

<0.001 1.27

0.95 - 1.70 0.107

Length of stay
(days)
≤7

(ref)

(ref)

8-14

3.35

2.94 - 3.81

<0.001 2.03

1.74 - 2.36 <0.001

15-21

4.48

3.79 - 5.29

<0.001 2.28

1.86 - 2.81 <0.001

>21

5.88

5.01 - 6.91

<0.001 2.72

2.18 - 3.39 <0.001

Footnote for Table 2:

PTZ: piperacillin-tazobactam; VAN: vancomycin; VAN/PTZ: vancomycin plus
piperacillin-tazobactam; CrCl: creatinine clearance; CCI: Charlson Comorbidity Index;
ACE: angiotensin converting enzyme; ARB: angiotensin receptor blocker; NSAID: nonsteroidal anti-inflammatory drug
16

Chapter Four: Conclusions
Summary of Findings
Acute kidney injury secondary to vancomycin therapy is a well characterized
adverse effect, while AKI incidence secondary to piperacillin-tazobactam is less
understood. Additionally, there appears to be an increased effect when these agents are
used in combination. To date, this is the largest review of AKI in patients receiving
vancomycin, piperacillin-tazobactam, or the combination of both agents.
There has been a recent surge in evidence suggesting increased nephrotoxicity in
patients treated with the combination of vancomycin and anti-pseudomonal beta-lactams.
The mechanism for the apparent increase in nephrotoxicity with the combination is not
well-understood and needs further study in both animal models and humans.
Acute kidney injury rates related to vancomycin vary widely, with recent studies in
critically ill and internal medicine patients estimating rates of 21% and 13.6%,
respectively.[2,3] In our vancomycin monotherapy cohort, which includes critically ill
patients, the AKI rate was 8.3%, with 2.3% of patients experiencing a greater than 50%
decrease in creatinine clearance. Piperacillin-tazobactam-related AKI rates are not wellcharacterized; however, a small retrospective analysis estimated that 11.1% of piperacillintazobactam patients experienced acute renal failure (defined as either increase in serum
creatinine ≥ 0.5 mg/dL or 50% increase from baseline).[13] In the present study, we found
the piperacillin-tazobactam-related AKI rate to be 7.8%, which may be due to a more
stringent definition of AKI. Additionally, Hellwig et al [13], found that piperacillintazobactam monotherapy was associated with higher AKI rates compared to vancomycin
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monotherapy (11.1% vs. 4.9%; p=0.014). This was not replicated in our study, with
vancomycin and piperacillin-tazobactam monotherapy having similar AKI rates (8.3% and
7.8%, respectively) and an adjusted odds ratio for AKI between piperacillin-tazobactam
and vancomycin of 0.88 (95% CI 0.72-1.07). The estimated AKI incidence in the
combination therapy group of 21% at our institution is consistent with prior literature which
ranges from 16.3 to 34.8%.[4-8, 13]
Limitations
This study is not without limitations. As with all retrospective studies, it is difficult
to determine a causal link between vancomycin and piperacillin-tazobactam combination
therapy and increased AKI incidence due to confounding. We employed a rigorous study
design that controlled for major confounders of AKI, such as concomitant nephrotoxic
exposure, hypotension, and previous renal disease. Nephrotoxic potential of agents was
assumed to be equal, which is not necessarily true. Additionally, the binary representation
of nephrotoxic exposure does not describe the amount of the agent received; as such, our
estimations of AKI odds may be artificially elevated. Approximately one quarter of the
patients in this study were transferred from an outside hospital, for which no data regarding
initial treatment is available. This may lead to exposure misclassification; however, we
attempted to control for this factor in the regression model and found that, after controlling
for other covariates, hospital transfer was not associated with odds of AKI. Finally, data
was collected retrospectively from the electronic medical record and is subject to
inaccuracies documented in the chart; however, any bias introduced should be
nondifferential.
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Application to Clinical Practice
In our large retrospective study of combination empiric therapy with vancomycin
and piperacillin-tazobactam, we found that combination therapy was associated with over
double the odds of AKI occurring compared to either monotherapy with vancomycin or
piperacillin-tazobactam. Increasing duration of therapy was also associated with increases
in AKI. These findings demonstrate the need for judicious use of combination therapy and
strengthen the need for antimicrobial de-escalation when appropriate in order to avoid
deleterious effects.
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Appendix A: R codes
#### Acute Kidney injury in Vanc mono vs. PTZ mono vs. PTZ+VAN
meds<-read.csv('../Desktop/AKI
data
files/New_meds.csv',
colClasses='character')
##Cleaning up the medication dataset for better analysis.
meds$drug<-meds$Name
##Using a separate
dataset so nothing is changed in the origninal unintentionally
meds$drug<-sub('Inj\\.','',meds$drug)
meds$drug<-sub('\\(Drip\\)','',meds$drug)
meds$drug<-sub('\\(PEDIATRIC\\)','',meds$drug)
meds$drug<-sub('\\(IntraMuscular\\)','',meds$drug)
meds$drug<-sub('-','',meds$drug)
meds$drug<-sub('Inj','',meds$drug)
library(stringr)
##Load the stringr
package for access to the str_trim which eliminates whitespace
meds$drug<-str_trim(meds$drug)
##generated in the
steps above
meds$drug<-sub('zzz','',meds$drug)
meds$drug<-sub('Piperacillin / Tazobactam','PTZ',meds$drug)
library(dplyr)
meds2<-select(meds, Encounter.ID, MRN, drug)
meds2<-unique(meds2)
library(data.table)
meds2<-as.data.table(meds2)
meds3<-dcast.data.table(data = meds2, Encounter.ID+MRN~drug)
for(i in 1:nrow(meds3)){
if(!is.na(meds3$Cefepime[i])
is.na(meds3$Vancomycin[i])){
meds3$group[i]='CM'
}
if(is.na(meds3$Cefepime[i])
is.na(meds3$Vancomycin[i])){
meds3$group[i]='PM'
}
if(is.na(meds3$Cefepime[i])
!is.na(meds3$Vancomycin[i])){
meds3$group[i]='VM'
}
if(is.na(meds3$Cefepime[i])
!is.na(meds3$Vancomycin[i])){
meds3$group[i]='PV'
}
if(!is.na(meds3$Cefepime[i])
!is.na(meds3$Vancomycin[i])){
meds3$group[i]='CV'
}
if(!is.na(meds3$Cefepime[i])
is.na(meds3$Vancomycin[i])){
meds3$group[i]='CP'
}
if(!is.na(meds3$Cefepime[i])
!is.na(meds3$Vancomycin[i])){
meds3$group[i]='CVP'
}

&

is.na(meds3$PTZ[i])

&

&

!is.na(meds3$PTZ[i])

&

&

is.na(meds3$PTZ[i])

&

&

!is.na(meds3$PTZ[i])

&

&

is.na(meds3$PTZ[i])

&

&

!is.na(meds3$PTZ[i])

&

&

!is.na(meds3$PTZ[i])

&
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}
demo<-read.csv('../Desktop/AKI
data
files/demo.csv',
colClasses='character')
##Imports RAW files
demo<-demo[demo$ENCNTR_ID %in% meds3$Encounter.ID,]
demo$EID<-demo$ENCNTR_ID
demo$ENCNTR_ID<-NULL
meds3$EID<-meds3$Encounter.ID
meds4<-select(meds3, EID, group)
demo2<-merge(demo, meds4, by='EID')
dat<-demo2[demo2$group %in% c('PM','PV','VM'),]
dat$AGE<-as.numeric(dat$AGE)
dat<-dat[dat$AGE>=18,]
dat$LENGTH_OF_STAY_NUM<-as.numeric(dat$LENGTH_OF_STAY_NUM)
dat<-dat[dat$LENGTH_OF_STAY_NUM>=2,]
meds<-meds[meds$Encounter.ID %in% demo2$EID,]
labs<-read.csv('../Desktop/AKI
data
files/New
Labs.csv',
colClasses='character')
labs<-labs[labs$ENCNTR_ID %in% dat$EID,]
scr<-labs[grepl('creatinine level', labs$ITEM_NAME, ignore.case = T),]
scr$date<-as.POSIXct(scr$ENTRD_DT_TM, format="%m/%d/%Y %I:%M:%S %p")
scr$VAL_NUM<-as.numeric(scr$VAL_NUM)
scr<-scr[!is.na(scr$VAL_NUM),]
scr$EID<-scr$ENCNTR_ID
dat<-dat[dat$EID %in% scr$EID,]
for(i in 1:nrow(dat)){
x<-scr[scr$EID == dat$EID[i],]
dat$baseline_scr_date[i]<-as.character(min(x$date))
dat$baseline_scr[i]<-x$VAL_NUM[x$date==min(x$date)]
}
for(i in 1:nrow(dat)){
x<-scr[scr$EID==dat$EID[i],]
dat$max_scr_date[i]<-as.character(x$date[x$VAL_NUM==max(x$VAL_NUM,
na.rm=T)])
dat$max_scr[i]<-max(x$VAL_NUM, na.rm=T)
}
class(meds$Performed.Date.Time)
meds$date<-sapply(strsplit(x = meds$Performed.Date.Time, split
'),'[',1)
van<-meds[grepl('vancomycin', ignore.case = T, meds$drug),]
ptz<-meds[grepl('PTZ', meds$drug),]
for( i in 1:nrow(dat)){
medx<-meds[meds$Encounter.ID == dat$EID[i],]
dat$Total_DOT[i]<-length(unique(medx$date))
}
for(i in 1:nrow(dat)){
if(dat$group[i]=='PV'){
vanx<-van[van$Encounter.ID == dat$EID[i],]
ptzx<-ptz[ptz$Encounter.ID == dat$EID[i],]
dat$Van_DOT[i]<-length(unique(vanx$date))

21

=

'

dat$PTZ_DOT[i]<-length(unique(ptzx$date))
}
if(dat$group[i]=='PM'){
dat$Van_DOT[i]<-NA
dat$PTZ_DOT[i]<-dat$Total_DOT[i]
}
if(dat$group[i]=='VM'){
dat$PTZ_DOT[i]<-NA
dat$Van_DOT[i]<-dat$Total_DOT[i]
}
}
medstest<-meds[meds$Encounter.ID %in% dat$EID,]
dot(medstest)
library(plyr)
dot2<-ldply(DOT_list)
dot3<-select(dot2, V1,V5)
dot3$EID<-dot3$V1
dot3$Combo_DOT<-dot3$V5
dot3$V1<-NULL
dot3$V5<-NULL
dat<-merge(dat, dot3, by='EID')
dat<-dat[dat$Total_DOT>=2,]
for(i in 1:nrow(dat)){
if(dat$GENDER[i]=='UNKNOWN'){
dat$GENDER[i]<-'MALE'
}
}
dat$baseline_scr<-as.numeric(dat$baseline_scr)
dat$max_scr<-as.numeric(dat$max_scr)
for(i in 1:nrow(dat)){
dat$baseline_crcl[i]<-(140-dat$AGE[i])/dat$baseline_scr[i]
dat$min_crcl[i]<-(140-dat$AGE[i])/dat$max_scr[i]
if(dat$GENDER[i]=='FEMALE'){
dat$baseline_crcl[i]<-dat$baseline_crcl[i]*0.85
dat$min_crcl[i]<-dat$min_crcl[i]*0.85
}
}
dat$percent_change<-(dat$min_crcl/dat$baseline_crcl-1)*100
for(i in 1:length(dat$EID)){
##assign
RIFLE labels to appropriate degrees of renal impairment
if (dat$percent_change[i]>=0){
##if
percent_change is >=0, the max SCr is equal to baseline, suggesting GFR
improvement
dat$RIFLE[i]<-"No injury"
}
else {
if (abs(dat$percent_change[i])<25){
dat$RIFLE[i]<-'No injury'
}
if (abs(dat$percent_change[i])>=25 & abs(dat$percent_change[i])<50){
dat$RIFLE[i] <-'RISK'
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}
if (abs(dat$percent_change[i])>=50 & abs(dat$percent_change[i])<75){
dat$RIFLE[i] <-'INJURY'
}
if (abs(dat$percent_change[i])>=75){
dat$RIFLE[i] <- 'Failure'
}
}
}
for(i in 1:length(dat$EID)){
binary outcome for AKI (Risk, Injury, Failure) vs No AKI
if(dat$RIFLE[i] =='No injury'){
convert to a 0/1 answer for modeling.
dat$AKI[i]<-"No AKI"
}
else{
dat$AKI[i]<-'AKI'
}
}
dat$van_start<-NA
dat$ptz_start<-NA
ptz$date<-as.Date(ptz$date, format='%m/%d/%Y')
van$date<-as.Date(van$date, format='%m/%d/%Y')
for(i in 1:nrow(dat)){
if(dat$group[i]=='PM'){
#x<-van[van$Encounter.ID==dat$EID[i],]
#x<-x[!is.na(x$date),]
#dat$van_start[i]<-as.character(min(x$date))
y<-ptz[ptz$Encounter.ID==dat$EID[i],]
y<-y[!is.na(y$date),]
dat$ptz_start[i]<-as.character(min(y$date))
dat$van_start[i]<-NA
}
if(dat$group[i]=='VM'){
x<-van[van$Encounter.ID==dat$EID[i],]
x<-x[!is.na(x$date),]
dat$van_start[i]<-as.character(min(x$date))
dat$ptz_start[i]<-NA
#y<-ptz[ptz$Encounter.ID==dat$EID[i],]
#y<-y[!is.na(y$date),]
#dat$ptz_start[i]<-as.character(min(y$date))
}
if(dat$group[i]=='PV'){
x<-van[van$Encounter.ID==dat$EID[i],]
x<-x[!is.na(x$date),]
dat$van_start[i]<-as.character(min(x$date))
y<-ptz[ptz$Encounter.ID==dat$EID[i],]
y<-y[!is.na(y$date),]
dat$ptz_start[i]<-as.character(min(y$date))
}
}
dat$ptz_start<-as.Date(dat$ptz_start)
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##Assigns
##Can

dat$van_start<-as.Date(dat$van_start)
for(i in 1:nrow(dat)){
dat$tx_index[i]<-as.character(min(dat$van_start[i],
na.rm = T))
}
dat$tx_index<-as.Date(dat$tx_index)

dat$ptz_start[i],

for(i in 1:nrow(dat)){
if(dat$group[i]=='PM' | dat$group[i]=='VM'){
dat$Combo_DOT[i]<-NA
}
}
dat<-dat[dat$Combo_DOT>=2 | is.na(dat$Combo_DOT),]
crclcut<-mean(dat$baseline_crcl)+4*sd(dat$baseline_crcl)
dat<-dat[dat$baseline_crcl<=crclcut,]
dat<-dat[dat$baseline_crcl>=30,]
dat$max_scr_date2<-sapply(strsplit(dat$max_scr_date, ' '),'[',1)
dat$max_scr_date2<-as.Date(dat$max_scr_date2)
for(i in 1:nrow(dat)){
if(dat$max_scr_date2[i] < dat$tx_index[i]){
dat$aki_before_tx[i]<-'Y'
}
else{
dat$aki_before_tx[i]<-'N'
}
}
dat<-dat[!(dat$aki_before_tx=='Y' & dat$AKI=='AKI'),]
for(i in 1:nrow(dat)){
if(dat$AKI[i]=='No AKI'){
dat$time_to_aki[i]<-NA
}
else{
dat$time_to_aki[i]<-as.numeric(dat$max_scr_date2[i]dat$tx_index[i])
}
}
dat_b<-dat
dat<-dat[dat$time_to_aki>=2 | is.na(dat$time_to_aki),]
dat$van_end<-NA
dat$ptz_end<-NA
for(i in 1:nrow(dat)){
if(dat$group[i]=='VM'){
x<-van[van$Encounter.ID==dat$EID[i],]
x<-x[!is.na(x$date),]
dat$van_end[i]<-as.character(max(x$date))
dat$ptz_end[i]<-NA
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}
if(dat$group[i]=='PM'){
dat$van_end[i]<-NA
y<-ptz[ptz$Encounter.ID==dat$EID[i],]
y<-y[!is.na(y$date),]
dat$ptz_end[i]<-as.character(max(y$date))
}
if(dat$group[i]=='PV'){
x<-van[van$Encounter.ID==dat$EID[i],]
x<-x[!is.na(x$date),]
dat$van_end[i]<-as.character(max(x$date))
y<-ptz[ptz$Encounter.ID==dat$EID[i],]
y<-y[!is.na(y$date),]
dat$ptz_end[i]<-as.character(max(y$date))
}
}
dat$van_end<-as.Date(dat$van_end)
dat$ptz_end<-as.Date(dat$ptz_end)
for(i in 1:nrow(dat)){
dat$tx_end[i]<-as.character(max(dat$van_end[i], dat$ptz_end[i], na.rm
= T))
}
dat$tx_end<-as.Date(dat$tx_end)
for( i in 1:nrow(dat)){
if(as.numeric(dat$tx_end[i] - dat$max_scr_date2[i])> 7){
dat$aki_out_range[i]<-'Y'
}
else{
dat$aki_out_range[i]<-'N'
}
}
dat<-dat[!(dat$aki_out_range=='Y' & dat$AKI=='AKI'),]
for(i
in
1:length(dat$EID)){
##gives a single Y/N variable for occurence of hypotension
ifelse(dat$MEAN_ARTERIAL_UNDER_60_FLG[i]=='Y'|dat$HYPOTENSION_FLG[i]=='
Y'|
##this excludes SBP < 100 mmHg flag as this really isn't defensible
dat$VASOPRESSORS_FLG[i]=='Y'|dat$INOTROPES_FLG[i]=='Y',
dat$hypotension[i]<-'Y',dat$hypotension[i]<-'N')
}
for(i in 1:length(dat$EID)){
##Y/N
for nephrotoxic drug exposure. Does not give a count.
ifelse(dat$ACYCLOVIR_FLG[i]=='Y'|
dat$AMINOGLYCOSIDES_FLG[i]=='Y'|dat$AMPHOTERICIN_B_FLG[i]=='Y'|
dat$ANGIOTENSIN_FLG[i]=='Y'|
dat$ANGIOTENSION_FLG[i]=='Y'|dat$COLISTIN_FLG[i]=='Y' |
dat$CYCLOSPORINE_FLG[i]=='Y'|
dat$FOSCARNET_FLG[i]=='Y'|
dat$LOOP_DIURETICS_FLG[i]=='Y'|
dat$NON_STEROIDAL_ANTI_FLG[i]=='Y'|
dat$SULFONAMIDES_FLG[i]=='Y'| dat$TACROLIMUS_FLG[i]=='Y'|
dat$TENOFOVIR_FLG[i]=='Y',dat$nephrotoxic_drug[i]<"Y",dat$nephrotoxic_drug[i]<-"N")
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}
labs<-labs[labs$ENCNTR_ID %in% dat$EID,]
meds<-meds[meds$Encounter.ID %in% dat$EID,]
ptz<-meds[meds$drug=='PTZ',]
van<-meds[meds$drug=='Vancomycin',]
dat$year<-sapply(strsplit(as.character(dat$tx_index), '-',),'[',1)
van$Dose<-as.numeric(van$Dose)
for(i in 1:nrow(van)){
if(van$UOM[i]=='gram'){
van$Dose[i]<-van$Dose[i]*1000
van$UOM[i]<-'MG'
}
}
for(i in 1:nrow(van)){
if(van$Dose[i]==1){
van$Dose[i]<-1000
}
if(van$Dose[i]==100){
van$Dose[i]<-1500
}
}
van$date<-sapply(strsplit(van$Performed.Date.Time, ' '),'[',1)
van$date<-as.Date(van$date, format='%m/%d/%Y')
for(i in 1:nrow(dat)){
if(dat$group[i]=='PM'){
dat$avg_daily_van_dose[i]<-NA
}
if(dat$group[i] %in% c('PV','VM')){
x<-van[van$Encounter.ID==dat$EID[i],]
dat$avg_daily_van_dose[i]<-mean(by(x$Dose, x$date, sum))
}
}
labs<-labs[labs$ENCNTR_ID %in% dat$EID,]
vtr<-labs[grepl('trough', labs$ITEM_NAME, ignore.case = T),]
vtr$VAL_NUM<-as.numeric(vtr$VAL_NUM)
vtr$date<-sapply(strsplit(vtr$ENTRD_DT_TM, ' '), '[',1)
vtr$date<-as.Date(vtr$date, format='%m/%d/%Y')
vtr<-vtr[!is.na(vtr$VAL_NUM),]
for(i in 1:nrow(dat)){
if(!(dat$EID[i] %in% vtr$ENCNTR_ID)){
dat$first_van_tr[i]<-NA
dat$first_van_tr_date[i]<-NA
dat$max_van_tr[i]<-NA
dat$max_van_tr_date[i]<-NA
}
if(dat$EID[i] %in% vtr$ENCNTR_ID){
x<-vtr[vtr$ENCNTR_ID==dat$EID[i],]
dat$first_van_tr[i]<-x$VAL_NUM[x$date==min(x$date)]
dat$first_van_tr_date[i]<-as.character(min(x$date))

26

dat$max_van_tr[i]<-max(x$VAL_NUM)
dat$max_van_tr_date[i]<as.character(x$date[x$VAL_NUM==max(x$VAL_NUM)])
}
}
dat$max_van_tr<-as.numeric(dat$max_van_tr)
dat$first_van_tr<-as.numeric(dat$first_van_tr)
for(i in 1:nrow(dat)){
if(!is.na(dat$first_van_tr[i])){
if(dat$first_van_tr[i]<10){
dat$first_van_tr_class[i]<-'subtherapeutic'
}
if(dat$first_van_tr[i]<15 & dat$first_van_tr[i]>=10){
dat$first_van_tr_class[i]<-'therapeutic_low'
}
if(dat$first_van_tr[i]<=20 & dat$first_van_tr[i]>=15){
dat$first_van_tr_class[i]<-'therapeutic_high'
}
if(dat$first_van_tr[i]>20){
dat$first_van_tr_class[i]<-'supratherapeutic'
}
}
if(!is.na(dat$max_van_tr[i])){
if(dat$max_van_tr[i]<10){
dat$max_van_tr_class[i]<-'subtherapeutic'
}
if(dat$max_van_tr[i]<15 & dat$max_van_tr[i]>=10){
dat$max_van_tr_class[i]<-'therapeutic_low'
}
if(dat$max_van_tr[i]<=20 & dat$max_van_tr[i]>=15){
dat$max_van_tr_class[i]<-'therapeutic_high'
}
if(dat$max_van_tr[i]>20){
dat$max_van_tr_class[i]<-'supratherapeutic'
}
}
}
for(i in 1:nrow(dat)){
if(is.na(dat$max_van_tr[i])){
dat$max_van_tr_class[i]<-NA
dat$first_van_tr_class[i]<-NA
}
}
for(i in 1:nrow(dat)){
if(dat$baseline_crcl[i]>=90){
dat$baseline_crcl_group[i]<-'>=90'
dat$baseline_crcl_group_num[i]<-'1'
}
if(dat$baseline_crcl[i]<90 & dat$baseline_crcl[i]>=60){
dat$baseline_crcl_group[i]<-'>=60 to <90'
dat$baseline_crcl_group_num[i]<-'2'
}
if(dat$baseline_crcl[i]<60 & dat$baseline_crcl[i]>=30){
dat$baseline_crcl_group[i]<-'>=30 to <60'

27

dat$baseline_crcl_group_num[i]<-'3'
}
}
for(i in 1:nrow(dat)){
if(dat$AKI[i] =='AKI'){
dat$aki_num[i]<-1
}
else{
dat$aki_num[i]<-0
}
}
for(i in 1:nrow(dat)){
if(grepl('TRANS', dat$ADMT_SRC_CD_DES[i])){
dat$transfer[i]<-1
}
else{
dat$transfer[i]<-0
}
}
for(i in 1:nrow(dat)){
if(grepl('HOSPICE',
dat$DISCHRG_DES[i])|
grepl('DEATH',
dat$DISCHRG_DES[i])){
dat$mortality[i]<-1
}
else{
dat$mortality[i]<-0
}
}
dat$TOTAL_CHARLSON_SCORE<-as.numeric(dat$TOTAL_CHARLSON_SCORE)
for(i in 1:nrow(dat)){
if(dat$AGE[i]>=65){
dat$age_65[i]<-'Y'
}
else{
dat$age_65[i]<-'N'
}
}
for(i in 1:nrow(dat)){
if(dat$AGE[i]<30){
dat$age_group[i]<-'<30'
}
if(dat$AGE[i]>=30 & dat$AGE[i]<50){
dat$age_group[i]<-'30 to <50'
}
if(dat$AGE[i]>=50 & dat$AGE[i]<65){
dat$age_group[i]<-'50 to <65'
}
if(dat$AGE[i]>=65 & dat$AGE[i]<80){
dat$age_group[i]<-'65 to <80'
}
if(dat$AGE[i]>=80){
dat$age_group[i]<-'>=80'
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}
}
for(i in 1:nrow(dat)){
if(dat$LENGTH_OF_STAY_NUM[i]>7){
dat$los_7[i]<-'Y'
}
else{
dat$los_7[i]<-'N'
}
}
dat$los_weeks<-dat$LENGTH_OF_STAY_NUM/7
for(i in 1:nrow(dat)){
if(dat$LENGTH_OF_STAY_NUM[i]<=7){
dat$los_group[i]<-'<=7'
}
if(dat$LENGTH_OF_STAY_NUM[i]>7 & dat$LENGTH_OF_STAY_NUM[i]<=14){
dat$los_group[i]<-'8-14'
}
if(dat$LENGTH_OF_STAY_NUM[i]>14 & dat$LENGTH_OF_STAY_NUM[i]<=21){
dat$los_group[i]<-'15-21'
}
if(dat$LENGTH_OF_STAY_NUM[i]>21){
dat$los_group[i]<-'>21'
}
}
for(i in 1:nrow(dat)){
if(dat$ANGIOTENSIN_FLG[i] =='Y' | dat$ANGIOTENSION_FLG[i]=='Y'){
dat$ace.arb[i]<-'Y'
}
else{
dat$ace.arb[i]<-'N'
}
}
for(i in 1:nrow(dat)){
if(dat$TACROLIMUS_FLG[i] =='Y' | dat$CYCLOSPORINE_FLG[i]=='Y'){
dat$tac.cyc[i]<-'Y'
}
else{
dat$tac.cyc[i]<-'N'
}
}
#begin simple models
x<-'binomial'
age<-glm(aki_num~AGE, family='binomial') #AGE as continuous variable
age65<-glm(aki_num~age_65, family='binomial', data=dat) # age as binary
>=65 variable
agegroup<-glm(aki_num~age_group, family='binomial', data=dat)
gender<-glm(aki_num~GENDER, family='binomial', data=dat)
cci<-glm(aki_num~TOTAL_CHARLSON_SCORE, family = 'binomial', data=dat)
adsrc<-glm(aki_num~ADMT_SRC_CD_DES, family='binomial', data=dat) #ugly
regression use adtype
adtype<-glm(aki_num~ADMT_TYP_CD_DES, family=x, data=dat)
los<-glm(aki_num~LENGTH_OF_STAY_NUM, family=x, data=dat)
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los7<-glm(aki_num~los_7, family=x, data=dat)
losw<-glm(aki_num~los_weeks, family=x, data=dat)
losg<-glm(aki_num~los_group, family=x, data=dat)
map<-glm(aki_num~MEAN_ARTERIAL_UNDER_60_FLG, family=x, data=dat)
dehy<-glm(aki_num~DEHYDRATION_FLG, family=x, data=dat)
hypof<-glm(aki_num~HYPOTENSION_FLG, family=x, data=dat)
acy<-glm(aki_num~ACYCLOVIR_FLG, family=x, data=dat)
ag<-glm(aki_num~AMINOGLYCOSIDES_FLG, family=x, data=dat)
ab<-glm(aki_num~AMPHOTERICIN_B_FLG, family=x, data=dat)
ace<-glm(aki_num~ANGIOTENSIN_FLG,family=x, data=dat)
arb<-glm(aki_num~ANGIOTENSION_FLG, family=x, data=dat)
acearb<-glm(aki_num~ace.arb, family=x, data=dat)
cyc<-glm(aki_num~CYCLOSPORINE_FLG, family=x, data=dat)
tac<-glm(aki_num~TACROLIMUS_FLG, family=x, data=dat)
taccyc<-glm(aki_num~tac.cyc, family=x, data=dat)
fos<-glm(aki_num~FOSCARNET_FLG, family=x, data=dat)
loop<-glm(aki_num~LOOP_DIURETICS_FLG, family=x, data=dat)
nsaids<-glm(aki_num~NON_STEROIDAL_ANTI_FLG, family=x, data=dat)
sulf<-glm(aki_num~SULFONAMIDES_FLG, family=x, data=dat)
ten<-glm(aki_num~TENOFOVIR_FLG, family=x, data=dat)
vas<-glm(aki_num~VASOPRESSORS_FLG, family=x, data=dat)
ino<-glm(aki_num~INOTROPES_FLG, family=x, data=dat)
txgroup<-glm(aki_num~group, family=x, data=dat)
tdot<-glm(aki_num~Total_DOT, family=x, data=dat)
vdot<-glm(aki_num~Van_DOT, x, dat)
pdot<-glm(aki_num~PTZ_DOT, x, dat)
crcl<-glm(aki_num~baseline_crcl, x, dat)
crclg<-glm(aki_num~factor(baseline_crcl_group),x,dat)
hypoc<-glm(aki_num~hypotension, x, dat)
neph<-glm(aki_num~nephrotoxic_drug, x, dat)
yr<-glm(aki_num~factor(year), x, dat)
vd<-glm(aki_num~avg_daily_van_dose, x, dat)
dat$avd_grams<-dat$avg_daily_van_dose/1000
vdg<-glm(aki_num~avd_grams, x, dat)
trans<-glm(aki_num~transfer, x, dat)
dat$group<-relevel(dat$group, ref = 'PV')
model1lrm<lrm(aki_num~group+age_65+TOTAL_CHARLSON_SCORE+transfer+DEHYDRATION_FLG+
ACYCLOVIR_FLG+AMINOGLYCOSIDES_FLG+AMPHOTERICIN_B_FLG+ANGIOTENSIN_FLG
+
LOOP_DIURETICS_FLG+TACROLIMUS_FLG+Total_DOT+baseline_crcl_group+hypoten
sion, data=dat)
model1glm<glm(aki_num~group+age_65+TOTAL_CHARLSON_SCORE+transfer+DEHYDRATION_FLG+
ACYCLOVIR_FLG+AMINOGLYCOSIDES_FLG+AMPHOTERICIN_B_FLG+ANGIOTENSIN_FLG
+
LOOP_DIURETICS_FLG+TACROLIMUS_FLG+Total_DOT+baseline_crcl_group+hypoten
sion, data=dat, x)
compmodelglm<-glm(aki_num~group
+
factor(age_group)
+
TOTAL_CHARLSON_SCORE+ factor(baseline_crcl_group)+ transfer+hypotension+
GENDER+
year+factor(los_group)+DEHYDRATION_FLG+ACYCLOVIR_FLG+AMINOGLYCOSIDES_FL
G+ AMPHOTERICIN_B_FLG+
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ace.arb+tac.cyc+FOSCARNET_FLG+LOOP_DIURETICS_FLG+NON_STEROIDAL_ANTI_FLG
+SULFONAMIDES_FLG+
TENOFOVIR_FLG+Total_DOT+nephrotoxic_drug, x, dat)
compmodellrm<-lrm(aki_num~group
+
factor(age_group)
+
TOTAL_CHARLSON_SCORE+ factor(baseline_crcl_group)+ transfer+hypotension+
GENDER+
year+factor(los_group)+DEHYDRATION_FLG+ACYCLOVIR_FLG+AMINOGLYCOSIDES_FL
G+ AMPHOTERICIN_B_FLG+
ace.arb+tac.cyc+FOSCARNET_FLG+LOOP_DIURETICS_FLG+NON_STEROIDAL_ANTI_FLG
+SULFONAMIDES_FLG+
TENOFOVIR_FLG+Total_DOT+nephrotoxic_drug, dat)
compsteplrm<-lrm(aki_num
~
group
+
factor(age_group)
+
TOTAL_CHARLSON_SCORE +
factor(baseline_crcl_group) + transfer + hypotension
+ GENDER +
year
+
factor(los_group)
+
DEHYDRATION_FLG
+
AMPHOTERICIN_B_FLG +
tac.cyc + LOOP_DIURETICS_FLG + NON_STEROIDAL_ANTI_FLG
+ TENOFOVIR_FLG +
Total_DOT + nephrotoxic_drug, dat)
finmodel1glm<-glm(aki_num
~
group
+
factor(age_group)
+
TOTAL_CHARLSON_SCORE +
factor(baseline_crcl_group) + transfer + hypotension
+ GENDER +
factor(year) + factor(los_group) + DEHYDRATION_FLG +
AMPHOTERICIN_B_FLG +
tac.cyc
+
LOOP_DIURETICS_FLG
+
NON_STEROIDAL_ANTI_FLG + TENOFOVIR_FLG +
Total_DOT,x, dat)
finmodel2lglm<-glm(aki_num~group
+
factor(age_group)
+
TOTAL_CHARLSON_SCORE+ factor(baseline_crcl_group)+ transfer+hypotension+
GENDER+
factor(year)+factor(los_group)+DEHYDRATION_FLG+ACYCLOVIR_FLG+AMINOGLYCO
SIDES_FLG+ AMPHOTERICIN_B_FLG+
ace.arb+tac.cyc+FOSCARNET_FLG+LOOP_DIURETICS_FLG+NON_STEROIDAL_ANTI_FLG
+SULFONAMIDES_FLG+
TENOFOVIR_FLG+Total_DOT, x, dat)
finmodel2lglm2<-glm(aki_num~group
+
factor(age_group)
+
TOTAL_CHARLSON_SCORE+ factor(baseline_crcl_group)+ transfer+hypotension+
GENDER+
factor(year)+factor(los_group)+DEHYDRATION_FLG+Total_DOT+nephrotoxic_dr
ug, x, dat)
finmodel2lrm<-lrm(aki_num~group
+
factor(age_group)
+
TOTAL_CHARLSON_SCORE+ factor(baseline_crcl_group)+ transfer+hypotension+
GENDER+
factor(year)+factor(los_group)+DEHYDRATION_FLG+ACYCLOVIR_FLG+AMINOGLYCO
SIDES_FLG+ AMPHOTERICIN_B_FLG+
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ace.arb+tac.cyc+FOSCARNET_FLG+LOOP_DIURETICS_FLG+NON_STEROIDAL_ANTI_FLG
+SULFONAMIDES_FLG+
TENOFOVIR_FLG+Total_DOT, dat)
finmodel2lrm2<-lrm(aki_num~group
+
factor(age_group)
+
TOTAL_CHARLSON_SCORE+ factor(baseline_crcl_group)+ transfer+hypotension+
GENDER+
factor(year)+factor(los_group)+DEHYDRATION_FLG+Total_DOT+nephrotoxic_dr
ug, dat)
dat$dc_date<-sapply(strsplit(dat$DISCHRG_DT, ' '),'[',1)
dat$dc_date<-as.Date(dat$dc_date, format='%m/%d/%Y')
dat$starttime<-0
for(i in 1:nrow(dat)){
if(dat$AKI[i]=='No AKI'){
dat$stoptime[i]<-as.numeric(dat$dc_date[i]-dat$tx_index[i])
}
if(dat$AKI[i]=='AKI'){
dat$stoptime[i]<-as.numeric(dat$time_to_aki[i])
}
}
for(i in 1:nrow(dat)){
if(dat$AKI[i]=='No AKI'){
dat$stoptime2[i]<-min(as.numeric(dat$tx_end[i]-dat$tx_index[i])+7,
as.numeric(dat$dc_date[i]-dat$tx_index[i]) )
}
if(dat$AKI[i]=='AKI'){
dat$stoptime2[i]<-as.numeric(dat$time_to_aki[i])
}
}
cxmod<coxph(S~group+factor(age_group)+nephrotoxic_drug+hypotension+DEHYDRATIO
N_FLG+
TOTAL_CHARLSON_SCORE+factor(baseline_crcl_group)+GENDER+factor(year),
data=dat)
dat_b<-dat
dat$age_group<-as.factor(dat$age_group)
treat<-with(dat, data.frame(group=levels(group),
age_group=rep(levels(age_group)[1],3),
nephrotoxic_drug=rep('N',3),#rep(levels(nephrotoxic_drug)[1],3),
hypotension=rep('N',3),
DEHYDRATION_FLG=rep('N',3),
TOTAL_CHARLSON_SCORE=rep(mean(TOTAL_CHARLSON_SCORE),3),
baseline_crcl_group=rep(levels(baseline_crcl_group)[1],3),
GENDER=rep("MALE",3),
year=rep(levels(year)[1],3)
#los_group=rep(levels(los_group)[1],3),
#Total_DOT=rep(mean(Total_DOT),3)
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))
plot(survfit(cxmod, newdata = treat),
col=c('red','blue', 'green'),
xlab='Days after treatment initiation',
ylab='Proportion without AKI',
conf.int=F)
legend('bottomright',
c('PTZ/VAN',
'PTZ',
'blue','green'))

'VM'),lty=1,col=c('red',

finmodel2glm<-glm(aki_num~group
+
factor(age_group)
+
TOTAL_CHARLSON_SCORE+ factor(baseline_crcl_group)+ transfer+hypotension+
GENDER+
factor(los_group)+DEHYDRATION_FLG+ACYCLOVIR_FLG+AMINOGLYCOSIDES_FLG+
AMPHOTERICIN_B_FLG+
ace.arb+tac.cyc+FOSCARNET_FLG+LOOP_DIURETICS_FLG+NON_STEROIDAL_ANTI_FLG
+SULFONAMIDES_FLG+
TENOFOVIR_FLG+Total_DOT, x, dat)
finmodel2lrm<-lrm(aki_num~group
+
factor(age_group)
+
TOTAL_CHARLSON_SCORE+ factor(baseline_crcl_group)+ transfer+hypotension+
GENDER+
factor(los_group)+DEHYDRATION_FLG+ACYCLOVIR_FLG+AMINOGLYCOSIDES_FLG+
AMPHOTERICIN_B_FLG+
ace.arb+tac.cyc+FOSCARNET_FLG+LOOP_DIURETICS_FLG+NON_STEROIDAL_ANTI_FLG
+SULFONAMIDES_FLG+
TENOFOVIR_FLG+Total_DOT, dat)
for(i in 1:nrow(dat)){
if(dat$Total_DOT[i]<=3){
dat$tdot_group[i]<-'2-3'
}
if(dat$Total_DOT[i]>=4 & dat$Total_DOT[i]<6){
dat$tdot_group[i]<-'4-5'
}
if(dat$Total_DOT[i]>=6 & dat$Total_DOT[i]<8){
dat$tdot_group[i]<-'6-7'
}
if(dat$Total_DOT[i]>=8 & dat$Total_DOT[i]<10){
dat$tdot_group[i]<-'8-9'
}
if(dat$Total_DOT[i]>=10 & dat$Total_DOT[i]<12){
dat$tdot_group[i]<-'10-11'
}
if(dat$Total_DOT[i]>=12 & dat$Total_DOT[i]<14){
dat$tdot_group[i]<-'12-13'
}
if(dat$Total_DOT[i]>=14)
dat$tdot_group[i]<-'>=14'
}
}
dat$tdot_week<-dat$Total_DOT/7
dat$tdot_group<-as.factor(dat$tdot_group)
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dat$tdot_group<-relevel(dat$tdot_group, ref = '2-3')
finmodel2glma<-glm(aki_num~group
+
factor(age_group)
+
TOTAL_CHARLSON_SCORE+ factor(baseline_crcl_group)+ transfer+hypotension+
GENDER+
factor(los_group)+DEHYDRATION_FLG+ACYCLOVIR_FLG+AMINOGLYCOSIDES_FLG+
AMPHOTERICIN_B_FLG+
ace.arb+tac.cyc+FOSCARNET_FLG+LOOP_DIURETICS_FLG+NON_STEROIDAL_ANTI_FLG
+SULFONAMIDES_FLG+
TENOFOVIR_FLG+ tdot_group, x, dat)
finmodel2lrma<-lrm(aki_num~group
+
factor(age_group)
+
TOTAL_CHARLSON_SCORE+ factor(baseline_crcl_group)+ transfer+hypotension+
GENDER+
factor(los_group)+DEHYDRATION_FLG+ACYCLOVIR_FLG+AMINOGLYCOSIDES_FLG+
AMPHOTERICIN_B_FLG+
ace.arb+tac.cyc+FOSCARNET_FLG+LOOP_DIURETICS_FLG+NON_STEROIDAL_ANTI_FLG
+SULFONAMIDES_FLG+
TENOFOVIR_FLG+tdot_group, dat)
MODEL<glm(aki_num~group+factor(age_group)+TOTAL_CHARLSON_SCORE+factor(baselin
e_crcl_group)+transfer+hypotension+GENDER+
factor(los_group)+DEHYDRATION_FLG+ACYCLOVIR_FLG+AMINOGLYCOSIDES_FLG+AMP
HOTERICIN_B_FLG+ANGIOTENSIN_FLG+ANGIOTENSION_FLG+
TACROLIMUS_FLG+FOSCARNET_FLG+CYCLOSPORINE_FLG+
LOOP_DIURETICS_FLG+NON_STEROIDAL_ANTI_FLG+SULFONAMIDES_FLG+TENOFOVIR_FL
G+
factor(tdot_group), x, dat)
MODELlrm<lrm(aki_num~group+factor(age_group)+TOTAL_CHARLSON_SCORE+factor(baselin
e_crcl_group)+transfer+hypotension+GENDER+
factor(los_group)+DEHYDRATION_FLG+ACYCLOVIR_FLG+AMINOGLYCOSIDES_FLG+AMP
HOTERICIN_B_FLG+ANGIOTENSIN_FLG+ANGIOTENSION_FLG+
TACROLIMUS_FLG+FOSCARNET_FLG+CYCLOSPORINE_FLG+
LOOP_DIURETICS_FLG+NON_STEROIDAL_ANTI_FLG+SULFONAMIDES_FLG+TENOFOVIR_FL
G+
factor(tdot_group), dat)
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SCHOLASTIC AND PROFESSIONAL HONORS
11/2015 – Present
The Medicines Company Infectious Disease
Pharmacotherapy Research Award
Society of Infectious Disease Pharmacists
04/2013

Student Research/Scholarship Award
Graduate School of Biomedical Sciences – College of
Pharmacy

05/2008 – 05/2013
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